We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · January 24, 2022

Imeglimin Add-On to Insulin Monotherapy in Japanese Patients With Type 2 Diabetes

Diabetes, Obesity & Metabolism

 

Additional Info

Diabetes, Obesity & Metabolism
Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period
Diabetes Obes Metab 2022 Jan 04;[EPub Ahead of Print], C Reilhac, J Dubourg, C Thang, JM Grouin, P Fouqueray, H Watada

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading